Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BUY ALERT! NEOT will open between $3.50-$5.00 tomorrow
http://www.marketwatch.com/story/neotheticss-stock-rockets-on-heavy-volume-after-merger-deal-2017-10-17?siteid=yhoof2&yptr=yahoo
BUY ALERT! All indicators pointing out NEOT will open between $3.50-$5.00 tomorrow
SELL-SELL-SELL- take money and run
BUY ALERT NEWS- Analyst’s mean target price for CYTX is $2.17
The EPS of Cytori Therapeutics, Inc. is strolling at -1.03. The company’s Market capitalization is $13.17M with the total Outstanding Shares of 209.67M.
Analyst’s mean target price for CYTX is $2.17 while analysts mean suggestion is 2.3.
http://www.stocknews.pro/2017/10/13/worth-watching-active-stocks-news-update-visa-inc-nyse-vfirst-bancorp-nyse-fbp-cytori-therapeutics-inc-nasdaq-cytx/
SELL-SELL-SELL DAY LARGE BLOCK SHARES WILL BE SOLD
NEWS(CYTX) Thursday, October 12, 2017 RSS Email Newsletters Put PRWeb on your site
Okyanos Center for Regenerative Medicine Announces New Treatment Option for Patients with Diffuse Scleroderma Based on STAR Trial Protocol
https://investorshub.advfn.com/secure/post_new.aspx?board_id=8904
$CERC BUY ALERT-TODAY 7th DAY TO REGAIN COMPLIANCE
BUY ALERT!-(CERC) Major Shareholder Acquires $8296377 Stock at market look 8k today Bullish
BUY ALERT $12.00 price objective on the stock
HC Wainwright restated their buy rating on shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in a research report report published on Thursday. They currently have a $12.00 price objective on the stock.
https://www.truebluetribune.com/2017/10/08/delmar-pharmaceuticals-inc-dmpi-earns-buy-rating-from-hc-wainwright.html
NEWS ALERT!-DelMar Pharmaceuticals $DMPI Receives Coverage Optimism Score of 0.08
https://www.tickerreport.com/banking-finance/2948637/delmar-pharmaceuticals-dmpi-receives-coverage-optimism-score-of-0-08.html
BUY ALERT $12.00 price objective on the stock
HC Wainwright restated their buy rating on shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in a research report report published on Thursday. They currently have a $12.00 price objective on the stock.
https://www.truebluetribune.com/2017/10/08/delmar-pharmaceuticals-inc-dmpi-earns-buy-rating-from-hc-wainwright.html
$CYTX NEWS ALERT !http://www.prweb.com/releases/2017/10/prweb14761238.htm Bullish
$CYTX BUY ALERT! I see $1.29 a share
https://www.americanbankingnews.com/2017/10/08/critical-review-cytori-therapeutics-cytx-vs-transenterix-trxc.html
BUY ALERT! I see $1.29 a share =Recent results from our STAR trial for scleroderma with the U.S. FDA and Japan and the EU Bullish October 3, 2017
Dr. Marc H. Hedrick
President & CEO
NEWS- BUY ALERT! I see $1.29 a share =Recent results from our STAR trial for scleroderma with the U.S. FDA and Japan and the EU Bullish October 3, 2017
Dr. Marc H. Hedrick
President & CEO
BUY ALERT! SEATTLE, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics (ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions,
https://finance.yahoo.com/news/atossa-genetics-announces-chimeric-antigen-120000744.html
SELL-SELL-SELL AND RUN
BUY ALERT NEWS-Institutional Inverter Angelus Private Equity Group, LLC to exchange $4,463,380 invested additional money to pay all outstanding dept
U.S. Energy Corp. (USEG)
https://finance.yahoo.com/news/u-energy-corp-announces-strategic-100000628.html
DENVER, Oct. 05, 2017-- U.S. Energy Corp. today announced an agreement to substantially reduce the Company’ s outstanding debt through an exchange transaction with APEG Energy II, L.P., the sole lender ...
BUY-BUY-BUY IT WILL GET $2.00 ANY TIME
$INPX SELL-SELL-SELL take your money and run
Unfortunately I think it will be SELL day at 4th of October 2017 , due that fact that was lower volume traded 3,472,113 buyers v. 3,185,176 sellers =indicates it was pop up for dumping .blocks of shares . SELL or NOT you shell decide . Good luck to all.
$CYTR is entitled to receive additional $343 million in milestone payments for aldoxorubicin Bullish
$CYTR TIME TO BUY/ NEWS FROM FDA=Majority shareholders VOTED NO for R/S =NASDAQ granted 180 days extensions Bullish
LOS ANGELES, Oct. 2, 2017 /PRNewswire
Corporate and Financial Cytrx Corp. (CYTR)
For a non-revenue-generating, development-stage life science company, a strong balance sheet will always be a key concern. CytRx ended the second quarter of 2017 with $55 million in cash. Subsequent to the close of the second quarter, the NantCell transaction brought in an additional $13 million through their purchase of CytRx common shares at $1.10 per share, an approximately 92% premium to the Company's stock price at that time. The Company also restructured and paid down $10 million of its existing debt during the third quarter.
During 2017, CytRx has made significant strides in advancing its lead oncology asset aldoxorubicin from a late-stage clinical asset to a partnered, pre-New Drug Application (NDA) candidate in the U.S. In July 2017, CytRx announced a strategic licensing transaction with NantCell, Inc., for the global rights to aldoxorubicin. Dr. Patrick Soon-Shiong, the CEO and founder of NantCell, developed, obtained regulatory approval for, and commercialized Abraxane®, another albumin-mediated cytotoxic agent which currently generates approximately $1B in annual sales. CytRx believes that Dr. Soon-Shiong's track record and expertise with albumin-mediated agents will prove invaluable as NantCell works to obtain regulatory approval for aldoxorubicin, with the goal of commercialization thereafter.
"In addition to the initial indication of soft tissue sarcomas, NantCell is planning to develop aldoxorubicin in combination with immuno-oncology agents and cutting edge natural killer (NK) cell-based therapies in multiple tumor types, including breast and brain cancers," said David Haen, CytRx's Vice President of Business Development and Investor Relations. "NantCell is a true innovator in the field of oncology and brings a deep appreciation for the clinical benefit that aldoxorubicin can offer patients. We are confident that placing the asset in their hands will maximize both its future clinical and commercial potential."
CytRx has been actively working with the NantCell team to transition the aldoxorubicin program, including both completed and ongoing studies. Both teams are diligently working toward the preparation of the NDA for aldoxorubicin as a new treatment for soft tissue sarcomas, as well as getting additional clinical trials underway. CytRx looks forward to seeing aldoxorubicin enter NantCell-initiated clinical trials in the near future.
LADRâ„¢ Technology Platform and CytRx's Future Oncology Pipeline
CytRx's internal R&D activities at its expanded laboratory in Freiberg, Germany, are now focused on developing new drug candidates generated from its proprietary LADRâ„¢ (Linker Activated Drug Release) discovery platform.
Ongoing preclinical data is being generated for several LADRâ„¢-derived ultra-high potency compounds, and CytRx researchers have obtained partial and complete responses in a variety of solid tumor animal models to date. Additional in vivo efficacy and toxicology testing is underway, and CytRx's goal is to file one or more new patent applications during the fourth quarter of 2017. The Company also hopes to nominate the next LADRâ„¢ candidate for clinical development by the end of 2017 and to submit these important preclinical data for presentation at an upcoming scientific meeting in 2018. CytRx is extremely eager to move these programs forward and is taking great care to select the correct clinical candidates in order to optimally position these molecules for success once they enter clinical trials.
CytRx's strategy is to pursue a two-pronged approach to advancing its ultra-high potency LADRâ„¢ conjugates. Once a candidate is selected for clinical testing, the Company will conduct the necessary preclinical studies to enable an Investigational New Drug (IND) application filing, with the goal of taking the first LADRâ„¢-discovered, ultra-high potency conjugate into clinical trials during 2018. If the selected conjugate is successful in early-stage clinical studies although there can be no guarantee, CytRx hopes to seek Breakthrough Designation from the FDA. In parallel with internally advancing its LADRâ„¢-discovered conjugates, the Company also plans to explore pre-clinical strategic alliances with large pharmaceutical partners where a collaboration could demonstrate the utility of the LADRâ„¢ platform.
https://finance.yahoo.com/news/cytrx-corporation-provides-business-highlights-130000626.html
CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting
Oral Presentation Highlighting Updated and More Detailed Results from Global Phase 3 Trial in STS
Results Continue to Demonstrate Significantly Prolonged PFS in North American and L-sarcoma Patients Compared to Standard Treatments, with Minimal or No Cardiotoxicity up to 40 Cycles
Poster Presentation Featuring Data from Phase 1/2 Trial Combining Aldoxorubicin with Ifosfamide/Mesna in First- and Second-Line STS Will Also Be Presented
http://www.prnewswire.com/news-releases/cytrx-to-present-global-phase-3-aldoxorubicin-clinical-data-in-patients-with-soft-tissue-sarcomas-at-the-2017-american-society-of-clinical-oncology-annual-meeting-300459626.html
I have 1.2 million shares VOTING NO FOR R/'S =because (CYTR) shares worth at list $4.80 a share
$1.10 end of the week -CytRx will receive up to $356 Million from NantCell Under the terms of the license agreement,
I recommend Strong BUY (CYTR)=Majority shareholders VOTED NO for R/S
$CYTR =I hop Majority shareholders VOTED NO for R/S Like I did.
I recommend Strong BUY (CYTR)=Majority shareholders VOTED NO for R/S
STRONG BUY CLOSING AT $0.59
http://stockznews.com/2017/09/28/inpixon-nasdaqinpx-hot-stock-of-the-day/
STRONG BUY CLOSING AT $0.59
http://stockznews.com/2017/09/28/inpixon-nasdaqinpx-hot-stock-of-the-day/
STRONG BUY CLOSING AT $0.59
Buy Alert! (CYTR) will go up to $1.10 any time, farther extinction will be Granted stay on NASDAQ- Please Vote NO for R/'S.
I have 1.2 million shares VOTING NO for R/'S =because (CYTR)
shares worth at list $4.80 a share, not a $0.40 a share like incompetent management think or Paid by management Lawyers Recommend .
STRONG BUY=CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting
http://www.prnewswire.com/news-releases/cytrx-to-present-global-phase-3-aldoxorubicin-clinical-data-in-patients-with-soft-tissue-sarcomas-at-the-2017-american-society-of-clinical-oncology-annual-meeting-300459626.html
CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting
http://www.prnewswire.com/news-releases/cytrx-to-present-global-phase-3-aldoxorubicin-clinical-data-in-patients-with-soft-tissue-sarcomas-at-the-2017-american-society-of-clinical-oncology-annual-meeting-300459626.html
$CYTR NEWS ALERT! NASDAQ granted 180 days Extensions August 28,2017 Bullish Bullish
I have 1.2 million shares VOTING NO FOR R/'S =because (CYTR)
shares worth at list $4.80 a share not a $0.58 a share like incompetent management think.
NASDAQ granted 180 days extensions from August 28,2017 Bullish